Innoviva Reports Second Quarter 2021 Financial Results

Logo
July 28, 2021 20:05 UTC
  • Royalties increased by 44% to $104.3 million in the second quarter of 2021, compared to the same quarter in 2020.
  • Repurchased GSK’s full 32% equity stake in Innoviva for $392 million purchase price.
  • Strategically invested an additional $20 million into Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a leader in anti-infectives development.

BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the second quarter ended June 30, 2021.

  • Gross royalty revenues of $104.3 million from Glaxo Group Limited (“GSK”) for the second quarter of 2021 included royalties of $65.9 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $12.0 million from global net sales of ANORO® ELLIPTA® and royalties of $26.4 million from global net sales of TRELEGY® ELLIPTA®.1
  • Increase in fair values of strategic equity and long-term investments of $45.3 million in the second quarter of 2021 was mainly due to higher net valuation, as of June 30, 2021.
  • Income before income taxes increased by 15% to $136.2 million, compared to the same quarter in 2020.
  • Net cash and cash equivalents, excluding $3.2 million cash balance attributable to a variable interest entity, totaled $40.1 million, and receivables from GSK totaled $104.3 million as of June 30, 2021.

Pavel Raifeld, Chief Executive Officer of Innoviva, Inc., stated, “Our royalty revenues grew 44% year over year, demonstrating continued strength and resilience in the face of the pandemic.”

“RELVAR®/BREO® ELLIPTA® global net sales increased meaningfully compared to the second quarter of 2020. U.S. net sales increased significantly, driven in part by a favorable adjustment. Non-U.S. sales increased by 13% as the ICS/LABA class growth decline was more than offset by beneficial adherence trends among existing patients. ANORO® ELLIPTA® global net sales increased by 7% in the second quarter of 2021. U.S. net sales decreased by 3% due to negative volume dynamics. Non-U.S. ANORO® ELLIPTA® net sales increased by 25% as the environment normalized. TRELEGY® ELLIPTA® global net sales increased by 69% in the second quarter of 2021, driven by strong volume growth and a favorable adjustment in the U.S. as well as strong launches in non-U.S. markets.”

Mr. Raifeld concluded, “Over the past quarter, we continued to execute on our strategy of creating shareholder value through operational excellence and strategic investments, deploying in excess of $400 million. We are pleased with the superior performance across all key aspects of our business, and we believe GSK equity stake repurchase to be a strategically and economically attractive transaction that ushered a new chapter in our story and strongly positioned us for continued success.”

Recent Highlights

  • GSK Net Sales:
    • Second quarter 2021 net sales of RELVAR®/BREO® ELLIPTA® by GSK were $439.5 million, up 45% from $303.8 million in the same quarter of 2020, with $212.3 million in net sales from the U.S. market and $227.2 million from non-U.S. markets.
    • Second quarter 2021 net sales of ANORO® ELLIPTA® by GSK were $184.0 million, up 7% from $172.3 million in the same quarter of 2020, with $106.0 million net sales from the U.S. market and $78.0 million from non-U.S. markets.
    • Second quarter 2021 net sales of TRELEGY® ELLIPTA® by GSK were $405.9 million, up 69% from $240.5 million in the same quarter of 2020, with $285.5 million in net sales from the U.S. market and $120.4 million in net sales from non-U.S. markets.
  • Capital Allocation:
    • In May 2021, the Company repurchased 32,005,260 shares of its common stock from GSK at $12.25 per share for a total amount (including related transaction fees) of $394.1 million. The repurchased shares represented all of GSK’s equity stake in the Company, which was approximately 32% of the Company’s shares.
    • During the second quarter of 2021, the Company’s wholly owned subsidiary, Innoviva Strategic Opportunities LLC, invested $20.0 million to acquire 10 million shares of Entasis’ common stock and warrants to purchase up to an additional 10 million shares of common stock at $2.00 per share. With this additional investment, Innoviva collectively owned approximately 60.6% of Entasis’ common stock as of June 30, 2021 in addition to the warrants.

1 For TRELEGY ® ELLIPTA®, the amount represents 100% of royalty payments made by GSK to Theravance Respiratory Company, LLC (“TRC”). Innoviva owns 15% of the economic interest in TRC.

About Innoviva

Innoviva, Inc. (referred to as “Innoviva”, the “Company”, or “we” and other similar pronouns), is a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, “FF/VI”), ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, “UMEC/VI”) and TRELEGY® ELLIPTA® (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva is also entitled to 15% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (“TRC”), relating to TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the “GSK Agreements”), which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

ANORO®, RELVAR®, BREO®, TRELEGY® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

Forward Looking Statements

This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives beyond the existing respiratory portfolio); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (“COVID-19”). Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

INNOVIVA, INC.
Condensed Consolidated Statements of Income
(in thousands, except per share data)
(Unaudited)
                 
    Three Months
Ended
  Six Months
Ended
  June 30,   June 30,
     

2021

     

2020

     

2021

     

2020

 
Revenue:                
Royalty revenue from a related party, net (1)  

$

100,806

   

$

68,946

   

$

186,324

   

$

147,624

 
Revenue from collaborative arrangements with a related party    

-

     

10,000

     

-

     

10,000

 
Total net revenue    

100,806

     

78,946

     

186,324

     

157,624

 
                 
Operating expenses:                
Research and development    

38

     

559

     

87

     

559

 
General and administrative    

4,228

     

2,596

     

10,214

     

5,159

 
Total operating expenses    

4,266

     

3,155

     

10,301

     

5,718

 
                 
Income from operations    

96,540

     

75,791

     

176,023

     

151,906

 
                 
Other income (expense), net    

(951

)

   

30

     

(1,384

)

   

98

 
Interest income    

20

     

158

     

50

     

1,460

 
Interest expense    

(4,745

)

   

(4,561

)

   

(9,439

)

   

(9,077

)

Changes in fair values of equity and long-term investments, net    

45,315

     

46,698

     

100,360

     

68,613

 
Income before income taxes    

136,179

     

118,116

     

265,610

     

213,000

 
Income tax expense, net    

25,333

     

19,891

     

45,069

     

35,823

 
Net income    

110,846

     

98,225

     

220,541

     

177,177

 
Net income attributable to noncontrolling interest    

21,898

     

21,381

     

37,470

     

34,896

 
Net income attributable to Innoviva stockholders  

$

88,948

   

$

76,844

   

$

183,071

   

$

142,281

 
                 
Basic net income per share attributable to Innoviva stockholders  

$

1.01

   

$

0.76

   

$

1.93

   

$

1.40

 
Diluted net income per share attributable to Innoviva stockholders  

$

0.90

   

$

0.69

   

$

1.73

   

$

1.27

 
                 
Shares used to compute basic net income per share    

88,423

     

101,324

     

94,858

     

101,280

 
Shares used to compute diluted net income per share    

100,639

     

113,545

     

107,096

     

113,527

 
                 
(1) Total net revenue from a related party is comprised of the following (in thousands):  
                 
    Three Months
Ended
  Six Months
Ended
June 30, June 30,
     

2021

     

2020

     

2021

     

2020

 
    (unaudited)   (unaudited)
                 
Royalties from a related party  

$

104,262

   

$

72,402

   

$

193,236

   

$

154,536

 
Amortization of capitalized fees paid to a related party    

(3,456

)

   

(3,456

)

   

(6,912

)

   

(6,912

)

Royalty revenue from a related party, net  

$

100,806

   

$

68,946

   

$

186,324

   

$

147,624

 
                 
INNOVIVA, INC.
Condensed Consolidated Balance Sheets
(in thousands)
         
    June 30,   December 31,
   

2021

 

2020

    (unaudited)    

(1)

 
         
Assets        
Cash, cash equivalents and marketable securities  

$

43,265

 

$

246,487

 
Other current assets    

104,996

   

95,571

 
Property and equipment, net    

19

   

28

 
Equity and long-term investments    

473,677

   

438,258

 
Capitalized fees paid to a related party, net    

118,341

   

125,253

 
Deferred tax assets, net    

48,690

   

93,759

 
Other assets    

162

   

214

 
Total assets  

$

789,150

 

$

999,570

 
         
         
Liabilities and stockholders’ equity        
Other current liabilities  

$

1,219

 

$

1,958

 
Accrued interest payable    

4,152

   

4,152

 
Convertible subordinated notes, net    

240,072

   

239,783

 
Convertible senior notes, net    

149,917

   

145,734

 
Other long-term liabilities    

45

   

106

 
         
Innoviva stockholders’ equity    

329,780

   

539,912

 
Noncontrolling interest    

63,965

   

67,925

 
         
Total liabilities and stockholders’ equity  

$

789,150

 

$

999,570

 
         
(1) The selected consolidated balance sheet amounts at December 31, 2020 are derived from audited financial statements.
         
INNOVIVA, INC.
Cash Flows Summary
(in thousands)
         
     
    Six Months Ended
June 30,
     

2021

     

2020

 
    (unaudited)
Net cash provided by operating activities  

$

168,721

   

$

153,275

 
Net cash provided by investing activities    

63,627

     

9,044

 
Net cash used in financing activities    

(435,570

)

   

(27,268

)

View source version on businesswire.com: https://www.businesswire.com/news/home/20210728006003/en/

Contacts

Investor & Media Contacts:
Sloane & Company
James Goldfarb
212-486-9500
jgoldfarb@sloanepr.com

 

Source: Innoviva, Inc.

Back to news